Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into Broad Clinical Labs’ omics offerings. The collaboration is intended to connect proteomics data with genomic disease risk models and precision oncology workflows, including use cases in clinical trials and population-scale multiomic studies. Nomic said Omni 1000 is built on bead-based nELISA technology designed to multiplex hundreds to thousands of immunoassays quickly with reduced antibody cross-reactivity. The platform supports immunoassays for more than 1,050 proteins with absolute quantification. Both companies said development work is underway, with jointly developed applications planned to launch in early 2027. Terms were not disclosed.